Last updated: October 7, 2026
Flagyl ER is an extended-release 750 mg metronidazole tablet approved for bacterial vaginosis in nonpregnant women. Its commercial position is structurally weak: FDA exclusivity has expired, generic metronidazole products compete with the brand, and immediate-release metronidazole and newer single-dose therapies reduce the value of once-daily extended release. Public company filings do not disclose standalone Flagyl ER revenue, so its financial trajectory is best assessed through market access, generic substitution, prescription volume, pricing, and the absence of a current patent moat.
What is Flagyl ER and what is it approved to treat?
Flagyl ER contains metronidazole, a nitroimidazole antimicrobial. The extended-release formulation is administered as a 750 mg tablet once daily for seven days for bacterial vaginosis in nonpregnant women.[1]
| Product |
Active ingredient |
Dose |
Formulation |
Primary U.S. indication |
| Flagyl ER |
Metronidazole |
750 mg once daily |
Extended-release tablet |
Bacterial vaginosis |
| Flagyl |
Metronidazole |
Typically 250 mg or 500 mg multiple times daily |
Immediate-release tablet |
Several anaerobic and protozoal infections |
| Solosec |
Secnidazole |
2 g single dose |
Oral granules |
Bacterial vaginosis and trichomoniasis |
| Clindamycin |
Clindamycin phosphate or hydrochloride |
Variable |
Oral, vaginal, or topical |
Bacterial vaginosis |
Flagyl ER’s clinical value is concentrated in reduced dosing frequency. It does not have the broad indication profile associated with immediate-release Flagyl. The formulation is also distinct from extended-release metronidazole products used in other markets or compounded settings.
When does Flagyl ER lose exclusivity?
Flagyl ER has lost all meaningful regulatory exclusivity in the United States. Its new drug application was approved in the early 2000s, and any three-year clinical-investigation exclusivity associated with the product would have expired years ago.[2]
FDA regulatory timeline
| Event |
Approximate timing |
Commercial consequence |
| FDA approval of Flagyl ER NDA 021731 |
2004 |
Launch of branded extended-release metronidazole |
| Initial three-year clinical exclusivity period |
Mid-2000s |
Temporary protection against certain competing approvals |
| Patent and formulation protection period |
Primarily late 2000s to early 2020s, depending on claim |
Potential protection for formulation claims |
| Generic extended-release competition |
After regulatory and patent barriers expired |
Price and share erosion |
| Current status |
No meaningful U.S. regulatory exclusivity |
Brand relies on residual prescribing and distribution |
The FDA Orange Book remains the primary source for listed patents and exclusivity associated with NDA 021731.[3] Any historic formulation patents should be treated as expired or commercially ineffective unless a current, enforceable patent listing is confirmed in the Orange Book or through a live litigation record.
What patents protect Flagyl ER?
Flagyl ER’s historic intellectual-property position centered on the extended-release metronidazole formulation rather than a new chemical entity. The active ingredient, metronidazole, has been used for decades and is not protected by an unexpired composition-of-matter patent.
The relevant patent categories were:
- Extended-release matrix or delivery technology.
- Tablet composition and dissolution profile.
- Manufacturing processes for controlled release.
- Method-of-use claims for bacterial vaginosis.
How strong is the Flagyl ER patent estate?
The current patent estate is weak from a market-exclusion perspective.
| Patent category |
Strategic value today |
Reason |
| Metronidazole active ingredient |
None |
Core compound is long off patent |
| Extended-release formulation |
Limited to none |
Historic claims have expired or no longer prevent generic substitution |
| Manufacturing process |
Low |
Generic manufacturers can use non-infringing processes |
| Bacterial-vaginosis method of use |
Low |
The indication is established and generic labels can use approved indications after applicable barriers expire |
| Device or delivery technology |
None material |
Flagyl ER is an oral tablet without a proprietary device |
Formulation patents can delay generic entry when they remain listed and enforceable. That is not the current commercial reality for Flagyl ER. A generic manufacturer can generally compete using an equivalent extended-release tablet if it satisfies FDA bioequivalence and quality requirements.
Are there Paragraph IV challenges to Flagyl ER?
Flagyl ER is not currently known as an active Paragraph IV litigation market. Any historic Paragraph IV challenge would have targeted listed formulation or method patents in the Orange Book. Those disputes would have been relevant before generic entry, but they do not create a present-day barrier to competition.
A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. The filing can trigger patent litigation and a 30-month stay of approval under the Hatch-Waxman framework.[4]
For Flagyl ER, the commercial question is no longer whether a patent challenge could open the market. The market is already exposed to generic competition. The relevant risks are manufacturing continuity, product availability, FDA compliance, and reimbursement economics.
What is the Orange Book status of Flagyl ER?
The Orange Book identifies approved drug products, therapeutic equivalence evaluations, patent information, and exclusivity data.[3] Flagyl ER’s Orange Book relevance is primarily historical because:
- NDA 021731 is an old small-molecule product.
- The active ingredient is generic and widely available.
- Any original exclusivity period has expired.
- Historic formulation patents do not provide a durable current barrier.
- Generic approval depends on product-specific bioequivalence and extended-release performance.
The presence of an AB-rated generic, where applicable, is commercially important because pharmacists and payers can substitute the generic for the branded product under state substitution laws and plan rules. Extended-release products require appropriate formulation-specific equivalence, so an immediate-release metronidazole tablet is not automatically an AB-rated substitute for Flagyl ER. It remains a strong therapeutic and economic competitor.
What generic entry risks exist for Flagyl ER?
Generic erosion is the central risk. Flagyl ER competes against both generic extended-release metronidazole and lower-cost immediate-release treatment.
Generic competition
Generic manufacturers can compete through:
- Extended-release metronidazole tablets equivalent to Flagyl ER.
- Immediate-release metronidazole tablets prescribed under different dosing schedules.
- Alternative oral anti-infective products.
- Vaginal and topical therapies for bacterial vaginosis.
Immediate-release metronidazole is particularly disruptive because it is inexpensive, familiar to prescribers, and supported by extensive clinical use. The extended-release product’s once-daily convenience is unlikely to support a large premium after generic entry.
Generic launch scenarios
| Scenario |
Expected market effect |
| One generic supplier |
Moderate price pressure; brand may retain limited contracted volume |
| Two or more generic suppliers |
Faster price erosion and payer substitution |
| Several suppliers with reliable inventory |
Brand volume declines sharply; market becomes commodity-driven |
| Supply disruption among generics |
Temporary recovery in branded or secondary-generic demand |
| Reimbursement exclusion |
Rapid loss of retail prescriptions |
The principal commercial barrier for new entrants is not patent protection. It is the relatively small market opportunity and the need to demonstrate extended-release product equivalence. That can limit the number of suppliers even when the legal market is open.
What is the FDA regulatory status of Flagyl ER?
Flagyl ER is an FDA-approved prescription product under NDA 021731.[1] Its approval does not provide current market exclusivity. The product is a conventional oral extended-release tablet, not a biologic, complex injectable, or drug-device combination.
Biosimilar risk
Flagyl ER has no biosimilar risk because metronidazole is a small-molecule drug. Competition occurs through the ANDA pathway for generic drugs, not through the 351(k) biosimilar pathway used for biologics.[5]
The regulatory risk profile is therefore simpler than that of biologics:
- No reference-product biosimilar interchangeability issue.
- No biologic manufacturing comparability requirement.
- No biologic exclusivity period.
- Primary regulatory requirements are pharmaceutical equivalence, bioequivalence, quality, labeling, and manufacturing compliance.
How does Flagyl ER compare with competing bacterial-vaginosis treatments?
Flagyl ER occupies a narrow position between inexpensive generic metronidazole and newer branded products.
| Product |
Dosing convenience |
Generic exposure |
Pricing position |
Commercial strength |
| Flagyl ER |
Once daily for seven days |
High |
Generally disadvantaged |
Low to moderate |
| Generic immediate-release metronidazole |
Multiple daily doses |
Very high |
Lowest-cost segment |
High |
| Solosec |
Single dose |
Branded |
Premium |
Differentiated but payer-sensitive |
| Clindamycin vaginal products |
Short-course local treatment |
High to moderate |
Variable |
Established alternative |
| Tinidazole |
Shorter oral regimens |
Generic |
Low to moderate |
Niche alternative |
Solosec, containing secnidazole, competes on single-dose administration and product differentiation rather than extended release.[6] Flagyl ER can offer a simpler regimen than multiple-dose immediate-release metronidazole, but it lacks the single-administration convenience of Solosec and lacks a durable proprietary position.
What is the financial trajectory for Flagyl ER?
No major pharmaceutical company publicly reports Flagyl ER revenue as a standalone product. Financial analysis must therefore rely on commercial indicators rather than a verified product-level sales series.
Revenue trajectory
The likely trajectory is:
- Initial branded revenue after launch, supported by the convenience of once-daily dosing.
- Gradual pressure from generic metronidazole and established low-cost immediate-release therapy.
- Declining brand prescriptions after generic extended-release entry.
- Lower net pricing caused by formulary exclusion, rebates, and substitution.
- Residual revenue from brand-loyal prescribers, supply gaps, legacy contracts, or limited formulary access.
- A mature, low-growth or declining product profile.
Flagyl ER is unlikely to be a material revenue contributor to a large pharmaceutical company. Its value is more likely to reside in residual cash flow, portfolio completeness, or a small specialty-generic opportunity than in growth.
Revenue exposure by market driver
| Driver |
Direction |
Impact |
| Generic substitution |
Negative |
Reduces branded volume |
| Immediate-release metronidazole |
Negative |
Caps premium pricing |
| Once-daily dosing |
Positive |
Supports clinical preference in selected patients |
| FDA-approved indication |
Positive |
Maintains label-based prescribing |
| Newer single-dose therapy |
Negative |
Reduces convenience differentiation |
| Supply shortages |
Temporary positive |
Can redirect demand to the brand |
| Payer formulary exclusion |
Negative |
Limits access and reimbursement |
| Patent expiry |
Negative |
Removes legal pricing support |
The absence of public product-level revenue data prevents a defensible estimate of annual sales, net price, or brand contribution margin. The business profile is nevertheless clear: Flagyl ER is a mature, generic-exposed oral anti-infective with limited pricing power.
What patent litigation affects Flagyl ER?
No current high-value patent litigation is publicly associated with Flagyl ER that would materially alter its U.S. market access. Historic litigation, if any, would have focused on generic entry and formulation patent claims.
The absence of active litigation matters commercially because:
- There is no visible 30-month stay risk affecting a new generic entrant.
- There is no current settlement restricting generic launch.
- There is no apparent injunction protecting branded volume.
- There is no identified litigation-driven exclusivity extension.
Are there licensing deals or settlement agreements for Flagyl ER?
No material current licensing transaction or generic settlement agreement is publicly associated with Flagyl ER. The product does not have the commercial profile of a high-value oncology, immunology, or specialty drug where launch-for-delay settlements and royalty-bearing licenses are common.
Any historical distribution or commercialization arrangements should be separated from patent settlements. A distributor relationship does not create exclusivity, and a legacy brand license would not restore expired patent protection.
What manufacturing and intellectual-property barriers remain?
Manufacturing is the main practical barrier, not intellectual property.
An extended-release metronidazole product must maintain:
- Controlled drug release over the intended dosing interval.
- Consistent dissolution performance.
- Tablet hardness and stability.
- Batch-to-batch content uniformity.
- Bioequivalence against the reference product.
- Compliance with FDA current good manufacturing practice requirements.
These requirements can reduce the number of commercially viable suppliers. They do not, however, create a durable moat if several manufacturers can produce an equivalent tablet.
Geographic protection is also limited. U.S. patents and FDA approvals govern the U.S. market, while other jurisdictions apply separate patent, regulatory, and substitution rules. The global opportunity is constrained by the widespread availability of generic metronidazole and local treatment guidelines.
What is the competitive outlook for Flagyl ER?
Flagyl ER’s competitive outlook is stable to declining in volume and weak in price. Its remaining differentiation is dosing convenience, but that advantage is limited by:
- Low cost of immediate-release metronidazole.
- Availability of single-dose secnidazole.
- Generic extended-release competition.
- Broad prescriber familiarity with older regimens.
- Payer preference for low-cost generic therapy.
- Limited clinical need for a proprietary extended-release product.
The most plausible commercial outcome is continued niche demand with declining brand economics. A temporary increase in demand could occur during generic shortages, manufacturing interruptions, or changes in payer coverage, but those conditions would not represent durable growth.
Key Takeaways
- Flagyl ER is a 750 mg once-daily extended-release metronidazole tablet for bacterial vaginosis.
- FDA exclusivity has expired, and the product has no meaningful current regulatory moat.
- Historic formulation patents are no longer a durable barrier to generic competition.
- Generic extended-release metronidazole and immediate-release metronidazole are the primary commercial threats.
- Flagyl ER has no biosimilar exposure because it is a small-molecule drug.
- No material current patent litigation, licensing transaction, or settlement agreement is publicly associated with the product.
- Standalone revenue is not publicly disclosed.
- The financial trajectory is consistent with mature, declining branded revenue and limited pricing power.
- Manufacturing complexity may restrict supplier count, but it does not restore market exclusivity.
- Flagyl ER’s residual value is likely concentrated in niche prescriptions, supply-driven demand, and legacy brand recognition.
FAQs
Is Flagyl ER still available in the United States?
Availability can vary by wholesaler, pharmacy, manufacturer, and payer. Generic metronidazole products are more commercially significant than the branded extended-release product.
Is Flagyl ER interchangeable with generic metronidazole?
Immediate-release generic metronidazole is not automatically therapeutically or pharmaceutically interchangeable with an extended-release tablet. Substitution depends on the specific FDA therapeutic-equivalence designation and state pharmacy law.
Does Flagyl ER have orphan-drug exclusivity?
No. Flagyl ER is not an orphan drug, and bacterial vaginosis is not an orphan indication.
Can a company obtain new patents on an extended-release metronidazole product?
A company may seek patents on genuinely novel formulation, manufacturing, or use claims. Any new patent would need to satisfy statutory requirements and would not automatically restore protection to the existing Flagyl ER product.
Is Flagyl ER more commercially attractive than Solosec?
Solosec has stronger differentiation because it is administered as a single dose, while Flagyl ER competes against inexpensive generic metronidazole. Flagyl ER may have lower development risk, but Solosec has the stronger branded convenience proposition.
References
- U.S. Food and Drug Administration. (2004). Flagyl ER (metronidazole) extended-release tablets prescribing information.
- U.S. Food and Drug Administration. (n.d.). New drug application exclusivity.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Patent certifications and 30-month stays.
- U.S. Food and Drug Administration. (n.d.). Biosimilar and interchangeable biosimilar products.
- U.S. Food and Drug Administration. (2017). Solosec (secnidazole) prescribing information.
